437 related articles for article (PubMed ID: 32461198)
1. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?
Tadic M; Cuspidi C; Mancia G; Dell'Oro R; Grassi G
Pharmacol Res; 2020 Aug; 158():104906. PubMed ID: 32461198
[TBL] [Abstract][Full Text] [Related]
2. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea.
Son M; Seo J; Yang S
Hypertension; 2020 Sep; 76(3):742-749. PubMed ID: 32654557
[TBL] [Abstract][Full Text] [Related]
3. Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients.
Pan W; Zhang J; Wang M; Ye J; Xu Y; Shen B; He H; Wang Z; Ye D; Zhao M; Luo Z; Liu M; Zhang P; Gu J; Liu M; Li D; Liu J; Wan J
Hypertension; 2020 Sep; 76(3):732-741. PubMed ID: 32654555
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19.
Li M; Dong Y; Wang H; Guo W; Zhou H; Zhang Z; Tian C; Du K; Zhu R; Wang L; Zhao L; Fan H; Luo S; Hu D
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1061-1067. PubMed ID: 32456948
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19.
Kow CS; Zaidi STR; Hasan SS
Am J Cardiovasc Drugs; 2020 Jun; 20(3):217-221. PubMed ID: 32281055
[TBL] [Abstract][Full Text] [Related]
6. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
Guo X; Zhu Y; Hong Y
Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
[No Abstract] [Full Text] [Related]
7. Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension.
Iaccarino G; Grassi G; Borghi C; Ferri C; Salvetti M; Volpe M;
Hypertension; 2020 Aug; 76(2):366-372. PubMed ID: 32564693
[TBL] [Abstract][Full Text] [Related]
8. Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.
Wang JJ; Edin ML; Zeldin DC; Li C; Wang DW; Chen C
Pharmacol Ther; 2020 Nov; 215():107628. PubMed ID: 32653530
[TBL] [Abstract][Full Text] [Related]
9. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
[No Abstract] [Full Text] [Related]
10. [Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.].
Limbourg FP
MMW Fortschr Med; 2020 May; 162(9):67-69. PubMed ID: 32405833
[TBL] [Abstract][Full Text] [Related]
11. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
12. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
Baral R; White M; Vassiliou VS
Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular molecular mechanisms of disease with COVID-19.
Foo R; Wang Y; Zimmermann WH; Backs J; Wang DW
J Mol Cell Cardiol; 2020 Apr; 141():107. PubMed ID: 32289321
[No Abstract] [Full Text] [Related]
14. [Hypertension, RAAS blockade and risk in COVID-19 patients].
Spaak J; Kahan T
Lakartidningen; 2020 Jun; 117():. PubMed ID: 32594472
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors.
Zhou X; Zhu J; Xu T
Clin Exp Hypertens; 2020 Oct; 42(7):656-660. PubMed ID: 32404011
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility and prognosis of COVID-19 patients with cardiovascular disease.
Wang BX
Open Heart; 2020 Jun; 7(1):. PubMed ID: 32587104
[No Abstract] [Full Text] [Related]
17. Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System.
Lumpuy-Castillo J; Lorenzo-Almorós A; Pello-Lázaro AM; Sánchez-Ferrer C; Egido J; Tuñón J; Peiró C; Lorenzo Ó
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899833
[TBL] [Abstract][Full Text] [Related]
18. Renin-angiotensin-aldosterone system and COVID-19 infection.
Alexandre J; Cracowski JL; Richard V; Bouhanick B;
Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
[TBL] [Abstract][Full Text] [Related]
19. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
20. [COVID-19 and the impact of cardiovascular comorbidities].
Seoudy H; Frey N
Dtsch Med Wochenschr; 2020 Aug; 145(16):1157-1160. PubMed ID: 32791552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
